T1	Participants 78 147	in severe neurological manifestations in systemic lupus erythematosus
T2	Participants 161 232	Severe neurological involvement in systemic lupus erythematosus (NPSLE)
T3	Participants 386 680	controlled clinical trial at two tertiary care centres of patients with SLE according to the ACR criteria, with incident (no more than 15 days) onset of severe NP manifestations such as seizures, optic neuritis, peripheral or cranial neuropathy, coma, brainstem disease, or transverse myelitis.
T4	Participants 1124 1185	32 patients studied, 18/19 receiving Cy and 7/13 receiving MP
